Page 24 - Service Testing News Today

By Chris Wack Harmony Biosciences Holdings shares rebounded 9% to $23.04 from Friday's drop, when the company said its Phase 3 study missed the primary...

By Will Feuer Shares of Omeros were cut nearly in half after the company said it is discontinuing its late-stage clinical trial evaluating its narsoplimab...

By Adam L. Cataldo Annovis Bio's shares gained after the company said an independent statistical group concluded that its Phase 2/3 study could continue as...

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

By Michael Susin Faron Pharmaceuticals Oyj said that study data from its acute myeloid leukemia treatment, Bexmarilimab, showed positive results. The...

By Robb M. Stewart Eupraxia Pharmaceuticals has initiated the second cohort for its early-stage trial in eosinophilic esophagitis as it continues to make...

Health-care companies fell as traders digested the mixed implications of blockbuster obesity drugs. Shares of Danish obesity-drug maker Novo Nordisk rallied...

By Ben Glickman Ventyx released results from its trial of VTX002 in the treatment of ulcerative colitis. The company found that its treatment had a...

By Colin Kellaher Merck & Co. on Tuesday said a Phase 3 study of its Keytruda cancer drug met the second of its dual primary endpoints as a perioperative...

Keytruda showed a 'statistically significant and clinically meaningful improvement' in overall survival in a late-stage trial.